Background
Methods
Patients
Treatment
Follow-up
Statistical analysis
Results
Patient characteristics and follow-up
Clinicopathologic Characteristics | Total (n = 316) | pCR (n = 70), % | Non-pCR (n = 246), % | P-value |
---|---|---|---|---|
Age (yrs) | 0.466 | |||
< 60 | 173 | 41(23.7%) | 132(76.3%) | |
≥ 60 | 143 | 29(20.3%) | 114(79.7%) | |
Sex | 0.056 | |||
Male | 219 | 42(19.2%) | 177(80.8%) | |
Female | 97 | 28(28.9%) | 69(71.1%) | |
Primary tumor Diameter | < 0.001* | |||
< 3 cm | 170 | 53(31.2%) | 117(68.8%) | |
≥ 3 cm | 146 | 17(11.6%) | 129(88.4%) | |
Macroscopic type | < 0.001* | |||
Exophytic type | 65 | 41(63.1%) | 24(36.9%) | |
Ulcerative type | 251 | 29(11.6%) | 222(88.4%) | |
Histological differentiation | 0.726 | |||
Well to moderately | 276 | 62(22.4%) | 214(77.6%) | |
Poorly | 40 | 8(20.0%) | 32(80.0%) | |
Clinical T stage | 0.434 | |||
T2 | 79 | 20 | 59 | |
T3-T4 | 237 | 50 | 187 | |
Clinical TNM stage | < 0.001* | |||
II | 153 | 51(24.4%) | 102(75.6%) | |
III | 163 | 19(11.7%) | 144(88.3%) |
Prognostic features of nCRT patients
Clinicopathologic Characteristics | n | Univariate | Multivariate | ||
---|---|---|---|---|---|
5-year overall survival rate | Hazard ratio (95% CI) | P-value | P-value | ||
Age (yrs) | 1.008(0.168–6.048) | 0.993 | |||
60 | 41 | 91.7% | |||
≥ 60 | 29 | 91.2% | |||
Sex | 0.358(0.040–3.205) | 0.335 | |||
Male | 42 | 89.0% | |||
Female | 28 | 95.2% | |||
Primary tumor Diameter | 6.138(1.022–36.869) | 0.023* | 0.076 | ||
< 3 cm | 53 | 95.2% | |||
≥ 3 cm | 17 | 78.7% | |||
Macroscopic type | 2.032(0.340–12.163) | 0.426 | |||
Exophytic type | 41 | 93.1% | |||
Ulcerative type | 29 | 89.0% | |||
Histological differentiation | 1.796(0.200–16.116) | 0.594 | |||
Well to moderately | 8 | 92.5% | |||
Poorly | 62 | 85.7% | |||
Clinical T stage | 0.323(0.054–1.938) | 0.191 | |||
T2 | 20 | 84.4% | |||
T3-T4 | 50 | 95.1% | |||
Clinical TNM stage | 6.917(1.133–42.216) | 0.015* | 0.038* | ||
II | 51 | 95.6% | |||
III | 19 | 74.7% |
Clinicopathologic Features | n | 5-year overall survival rate | Hazard ratio (95% CI) | P-value |
---|---|---|---|---|
Age (yrs) | 0.714 (0.438–1.162) | 0.171 | ||
< 60 | 132 | 60.5% | ||
≥ 60 | 114 | 69.0% | ||
Sex | 0.943 (0.556–1.599) | 0.826 | ||
Male | 177 | 61.5% | ||
Female | 69 | 69.8% | ||
Primary tumor Diameter | 1.254 (0.779–2.020) | 0.348 | ||
< 3 cm | 117 | 70.1% | ||
≥ 3 cm | 129 | 57.4% | ||
Macroscopic type | 1.406 (0.607–3.259) | 0.422 | ||
Exophytic type | 222 | 68.8% | ||
Ulcerative type | 24 | 64.2% | ||
Histological differentiation | 1.771 (0.985–3.186) | 0.052 | ||
Well to moderately | 214 | 67.3% | ||
Poorly | 32 | 45.0% | ||
Clinical TNM stage | 1.811 (1.084–3.025) | 0.021* | ||
II | 102 | 71.2% | ||
III | 144 | 59.0% | ||
Neoadjuvant pathologic TNM stage | 2.704 (1.811–4.038) | < 0.001* | ||
I | 51 | 96.0% | ||
II | 94 | 66.4% | ||
III | 101 | 49.7% |
Hazard ratio | 95% CI | P | |
---|---|---|---|
Step 1 | |||
Histological differentiation | 0.069 | ||
Clinical TNM stage | 1.811 | 1.084–3.025 | 0.023* |
Step 2 | |||
Clinical TNM stage | 0.974 | ||
Neoadjuvant pathologic TNM stage | 2.704 | 1.811–4.038 | < 0.001* |